BLASUBCUTANEOUSINJECTION
Approved
Dec 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
3/8 — Basic
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EXDENSUR (depemokimab) is a monoclonal antibody (mAb) approved by GSK in December 2025 as a subcutaneous injection. The specific indication and mechanism of action are not yet publicly detailed in available data, but as a newly launched biologic, it represents a significant addition to GSK's immunology or specialty care portfolio.
Growth
As a recently launched mAb, EXDENSUR will require substantial commercial infrastructure including field sales, medical affairs, and marketing support, with team size expected to grow during early market penetration.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
Started Mar 2026
456 enrolled
Asthma
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
Started Oct 2025
1,196 enrolled
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
Started Jun 2025
960 enrolled
Pulmonary Disease, Chronic Obstructive
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
Started Jun 2025
981 enrolled
Pulmonary Disease, Chronic Obstructive
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Started Jun 2025
150 enrolled
Asthma
Worked on EXDENSUR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.